ART with long-term effects without immunosuppression

Published Date: 02 Mar 2023

The latest studies of long-acting ART show benefits even in people who are not immune. Meanwhile, early proof-of-concept results for twice-yearly injection are encouraging.

Read Full News

Latest News

Is AD Transmissible? The Evidence for ‘Iatrogenic’ Disease

Evidence for medically transmitted amyloid pathology is mounting, but whether Alzheimer’s disease itself can be transmitted — and what it means for patients — remains unsettled.

Dr Reddy's Signs India Distribution Deal for Takeda's Qdenga Dengue Vaccine

Dr Reddy's Laboratories said on Friday it had ⁠signed an agreement with Japanese drugmaker Takeda Pharmaceutical to ⁠promote and distribute the Qdenga dengue vaccine in...

Screwworm Infests US Horse Before Port Reopens to Mexican Livestock

The U.S. confirmed a case of New World screwworm in a horse in New Mexico on Thursday, as the ⁠federal government prepared to resume imports of Mexican livestock into the...

CDC Delay Holds Up Children's COVID Vaccine Orders, WSJ Reports

U.S. states are facing delays in obtaining COVID-19 vaccines for children through a federal immunization program, the Wall Street Journal reported ⁠Wednesday, citing people...

Exclusive-Pennsylvania Asks for CDC Measles Help Amid Kennedy Dispute

The Pennsylvania health department has requested emergency support from the US CDC as it grapples with one of the country's largest and most deadly measles outbreaks, though...

Older Adults Living With HIV: A New Focus on Healthy Aging

The growing number of older adults with HIV brings multimorbidity, functional decline, stigma, and end-of-life planning to long-term care.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Latest News

Evidence for medically transmitted amyloid pathology is mounting, but whether Alzheimer’s disease itself can be transmitted — and what it means for patients — remains unsettled.

Dr Reddy's Laboratories said on Friday it had ⁠signed an agreement with Japanese drugmaker Takeda Pharmaceutical to ⁠promote and distribute the Qdenga dengue vaccine in...

The U.S. confirmed a case of New World screwworm in a horse in New Mexico on Thursday, as the ⁠federal government prepared to resume imports of Mexican livestock into the...

U.S. states are facing delays in obtaining COVID-19 vaccines for children through a federal immunization program, the Wall Street Journal reported ⁠Wednesday, citing people...

The Pennsylvania health department has requested emergency support from the US CDC as it grapples with one of the country's largest and most deadly measles outbreaks, though...

The growing number of older adults with HIV brings multimorbidity, functional decline, stigma, and end-of-life planning to long-term care.

News All Time

Daily Probiotic Fails to Prevent Infections in Infants

Daily use of an oral probiotic from 6 to 24 months of age may not reduce the occurrence of ear or respiratory tract infections and antibiotic use in healthy infants.

Once-Monthly PrEP Drug Could Be Manufactured for $3 a Year

The current agreement manufacturer Merck has signed for global access to its once-monthly alimatravir would exclude countries with more than 230,000 new HIV acquisitions a year.

Testing for Duffy-Null Neutrophil Count Before Consult

By adding Duffy antigen testing to routine blood bank screens, VA identified 79 DANC patients, sparing many unnecessary bone marrow biopsies.

WHO Says Staff Shortage, Funding Challenges Hamper Congo Ebola Response

Shortages of trained staff, operational partners and funding are causing a bottleneck in efforts to expand the Ebola response in the Democratic Republic of Congo as the...

Lessons From Recent Viral Outbreaks

Despite advances in diagnostics and trial speeds, gaps in clinical care capacity, targeted therapies, and public communication threaten global preparedness for the next pandemic.

Cyclosporiasis Cases in Michigan Climb to Over 14,700, State Health Officials Say

Michigan health officials reported 14,718 cases linked to an outbreak of cyclosporiasis on Thursday, an increase ⁠of 208 cases since its last update a week...

Salmonella Outbreak Linked to Pumpkin Seeds Infects 81 in France

An outbreak of salmonella related to ⁠a batch of pumpkin seeds infected 81 people, ⁠hospitalising six, in several French regions between ⁠May and August, ‌the Health and...

As Schools Re-open, Congo Drops Remote Learning Plan in Ebola Red Zone

Schools reopened this week in areas of Democratic Republic of Congo hardest hit by Ebola, after authorities decided the risk of transmission ⁠was outweighed by the risk of...

WHO's Tedros Says Ebola Response Must Be Scaled Up to Tackle Congo Outbreak

The head of the World Health Organization on Wednesday said the Ebola response needs to be scaled up to tackle the outbreak in the Democratic Republic ⁠of Congo, with...

Gepotidacin as Effective as Standard Therapy for Gonorrhea

Nucleic acid amplification test-confirmed success rates for urogenital gonorrhea are high and similar to those of oral gepotidacin and ceftriaxone plus azithromycin, a phase 3 trial shows.

Health Officials Turn to Mobile-phone Data to Track Ebola Spread in Congo

Health officials battling the Ebola outbreak in eastern Democratic Republic of Congo are using anonymised mobile-phone data to map population movements and identify areas...

GSK to Advance MRNA Flu Vaccine to Late-stage Trial

(Corrects paragraph 4 to clarify that GSK plans to start more than 20, ⁠not 25, late-stage trials in 2026)

UK Pledges Additional £50 Million to Help Contain Ebola Outbreak in Congo

Britain said on Tuesday it would provide more than £50 ⁠million ($67.56 million) in new funding to support efforts to contain an ⁠Ebola outbreak in the Democratic Republic...

Congo's Ebola Outbreak Kills More Than 3,000, Government Figures Show

The number of deaths in Democratic Republic of Congo's Ebola outbreak has surpassed 3,000, government ⁠data showed on Wednesday, as the country's worst-ever epidemic...

USDA Cyclospora Research Projects Shelved Amid Funding Cuts and Relocations, Politico Reports

The Trump administration is shuttering two of the three U.S. Department of Agriculture research projects studying cyclospora, ⁠a foodborne parasite that has sickened...

Measles Cases in Pennsylvania Rise to 460 Amid Ongoing Outbreak

Pennsylvania's health department said on Friday the confirmed number of cases linked to a measles ⁠outbreak has reached 460 this year, an increase of 36 over its update two...

Recommended News For You

The FDA Approves the New Frontline Aggressive ALL Regimen.

Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?

Scream, It's Good for You; Release the Cancer Pigeons; Talk of Chemo Rationing

Why Encouragement May Not Improve Motivation in Depression

Study Homes In on Simpler Lung Cancer Screening Criteria

Studies show that treatment for non-Hodgkin's lymphoma is also focused on the lymphoma.

24 months after radical prostateectomy, no PSA recurrence was observed when using apalutamide plus ADT.

Recommended Articles For You

Emerging Therapies Using Tumor-Activated Prodrug Systems for Selective Cancer Cell Killing 

New Anticoagulants: Balancing Efficacy and Safety in Patients with Atrial Fibrillation 

Tumor-Adjacent Tissue Regeneration Models: Scientific Foundations and Clinical Implications 

A Visual Journey Through Penile Cancer: Examining the Impact of Photos 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study finds primary-care doctors often overlook prostate cancer risk in Black men

2.

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

5.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

1.

Esaxerenone in Patients with Uncontrolled Hypertension Despite Existing Therapy: A Comprehensive Review

2.

Extracellular Vesicle Markers of Platelet Activation: Clinical Relevance and Emerging Insights

3.

Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond

4.

Hematopoietic Aging Signatures and Future Hematologic Disease Risk

5.

Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

2.

Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL

3.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

4.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment

5.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot